The NHIA approved a number of new drugs for NHI coverage and expanded coverage on February 17. Newly covered drugs include breakthrough new drugs for pediatric solid tumors, medications for fungal infections expanding coverage to children aged over one month, medications for respiratory syncytial virus (RSV) for premature babies born at less than 33 weeks of gestation; also, immunological agents have been approved for children five years of age with ulcerative colitis.

According to Dr. Po-Chang Lee, Director General of the NHIA, the NHIA has recently proposed a plan for copayment adjustments. Rather than increasing financial resources for the NHI, it is to enhance the public awareness of cost, and thereby optimize both the patients' health seeking behavior and patient-doctor shared decision-making. It is hoped that the public will value limited medical resources and reduce unnecessary medical care. Then, limited medical resources can be allocated to, such as new drugs, new technologies, and new medical devices, for those who really need them.